Las Vegas, NV -- (SBWIRE) -- 12/10/2013 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more .EquityObserver.com issues a special report on the following stocks: DragonWave, Inc. (USA) (NASDAQ:DRWI), Curis, Inc. (NASDAQ:CRIS),Amarin Corporation plc (ADR) (NASDAQ:AMRN), Delcath Systems, Inc. (NASDAQ:DCTH)
DragonWave, Inc. (USA) (NASDAQ:DRWI) managed to keep its gain at 16.53% on above-normal volume of 2.43M shares. The stock settled at $1.41 after floating in a range of $1.25 to $1.42. Its latest price has reached market capitalization of $70.53 million. Its 52-week range has been $1.08 to $3.74. DragonWave Inc. (DragonWave) is in the business of developing broadband wireless backhaul and pseudowire equipment. The Company is a provider of wireless Ethernet equipment used in Internet protocol (IP) networks. DragonWave designs, develops, markets and sells carrier-grade microwave radio frequency networking equipment (referred to as links), that wirelessly transmit broadband voice, video and other data between two points. Its wireless carrier-Ethernet links, which are based on a native Ethernet platform, function as a wireless extension to an existing fiber and global optic core telecommunications network.
For How Long DRWI will fight for Profitability? Read This Trend Analysis report
Curis, Inc. (NASDAQ:CRIS) traded down on a volume of 2.30 million, higher than its standard daily volume. Shares have dropped-18.86% to $2.79. Over the last twelve months, the stock has lost-8.52% and faced a worst price of $2.66. Curis, Inc. is a drug discovery and development company that is committed to leveraging signaling pathway drug technologies in seeking to develop next generation network-targeted cancer therapies. The Company conducts its research and development programs both internally and through strategic collaborations. Its advanced program is Hedgehog pathway inhibitor program under collaboration with Genentech, Inc.
Has CRIS Found The Bottom And Ready To Gain Momentum? Find Out Here
Amarin Corporation plc (ADR) (NASDAQ:AMRN) settled -222.26% lower at $1.73 on below -normal volume of 2.17M shares during the last trading day. The stock has its 12-month high at $6.30 and 52-week low price was $2.17. It traded in a range of $1.71 to $1.81 during the last trading day. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011.
Will AMRN Get Buyers Even After The Recent Rally? Find Out Here
In the last trading session, Delcath Systems, Inc. (NASDAQ:DCTH) showed no change on high volume, trading at a volume of 2.23M versus its average daily volume of 1.17 million shares. At $0.260, the stock has attained market capitalization of 32.84 million. Delcath Systems, Inc. (Delcath) is a development-stage, specialty pharmaceutical and medical device company, focused on oncology, initially cancers in the liver. Delcath focuses on the development and clinical study of the Delcath chemosaturation system.
Can DCTH Show a Strong Recovery? Find out in This Research Report
About Equity Observer:
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/" rel="nofollow" href="http://www.equityobserver.com/"> http://www.equityobserver.com/>
Employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)